Management of Interstitial Lung Disease Exacerbation

Initial Assessment and Differential Diagnosis

• The American Thoracic Society recommends immediately evaluating patients with acute respiratory worsening in the context of ILD for infectious etiologies, pulmonary embolism, pneumothorax, aspiration events, lymphoproliferative disorders, and drug-induced lung disease 1, 4
• Patients should be assessed for alternative causes of respiratory deterioration, including bacterial, viral, and fungal pneumonia 1, 4

Acute Pharmacologic Management

• High-dose intravenous corticosteroids, such as IV methylprednisolone up to 1 gram per day, are recommended as first-line therapy for patients experiencing an ILD exacerbation with acute or subacute respiratory deterioration 1, 2, 3
• The evidence quality for this recommendation is based on anecdotal reports and has a weak recommendation with very low-quality evidence 2, 3

Supportive Care Measures

• The British Thoracic Society recommends initiating long-term oxygen therapy if resting PaO₂ ≤7.3 kPa (55 mmHg) or if PaO₂ ≤8 kPa (60 mmHg) in the presence of peripheral edema or pulmonary hypertension 5, 6
• Oxygen saturation should be monitored at rest and with exertion, and supplemental oxygen prescribed if desaturation below 88% occurs during a 6-minute walk test 4

Special Considerations by ILD Subtype

• For connective tissue disease-associated ILD with acute exacerbation, high-dose IV corticosteroids are recommended as first-line therapy, with rituximab or cyclophosphamide as second-line escalation if refractory 1
• For idiopathic pulmonary fibrosis exacerbation, corticosteroids remain first-line despite very low-quality evidence, and chronic glucocorticoids should be avoided in stable IPF as they are associated with increased mortality 2, 3, 8

Management of Concurrent Pulmonary Hypertension

• Right heart catheterization is required to confirm the presence and severity of pulmonary hypertension, as echocardiography is inaccurate in fibrotic lung disease 9, 4
• Pulmonary vasodilators should generally be avoided in most ILD patients with PH, except in cases of moderate-to-severe PH documented by right heart catheterization 2, 3, 7

Prognosis and Transplant Consideration

• Early lung transplant referral should be considered for rapidly progressive ILD, as median survival post-transplant is 5.2-6.7 years compared to <2 years without transplant in advanced disease 8
• Acute exacerbation carries high mortality despite treatment, emphasizing the importance of aggressive supportive care 2, 3